✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Tamibarotene is an investigational drug.
There have been 11 clinical trials for Tamibarotene. The most recent clinical trial was a Phase 2 trial, which was initiated on February 8th 2021.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Promyelocytic, Acute. The leading clinical trial sponsors are Syros Pharmaceuticals, CytRx, and Japan Agency for Medical Research and Development.
There are four hundred and twenty-five US patents protecting this investigational drug and four international patents.
Recent Clinical Trials for Tamibarotene
|SY-1425 Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML||Syros Pharmaceuticals||Phase 2|
|Investigator-initiated Clinical Trial of MIKE-1||Japan Agency for Medical Research and Development||Phase 1/Phase 2|
|Investigator-initiated Clinical Trial of MIKE-1||Nagoya University||Phase 1/Phase 2|
Top disease conditions for Tamibarotene
Top clinical trial sponsors for Tamibarotene
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tamibarotene||See Plans and Pricing||Anticancer agent||Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP)||See Plans and Pricing|
|Tamibarotene||See Plans and Pricing||Pyrrolidinone derivatives as MetAP-2 inhibitors||Merck Patent GmbH (Darmstadt, DE)||See Plans and Pricing|
|Tamibarotene||See Plans and Pricing||.beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof||Quadriga Biosciences, Inc. (Los Altos, CA)||See Plans and Pricing|
|Tamibarotene||See Plans and Pricing||Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)||BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)||See Plans and Pricing|
|Tamibarotene||See Plans and Pricing||Aryl-cyanoguanidine compounds||Bayer Pharma Aktiengesellschaft (Berlin, DE)||See Plans and Pricing|
|Tamibarotene||See Plans and Pricing||Heteroaryl compounds as IRAK inhibitors and uses thereof||Merck Patent GmbH (Darmstadt, DE)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Tamibarotene||Australia||AU2015272560||2034-06-09||See Plans and Pricing|
|Tamibarotene||Canada||CA2951627||2034-06-09||See Plans and Pricing|
|Tamibarotene||Denmark||DK3153508||2034-06-09||See Plans and Pricing|
|Tamibarotene||European Patent Office||EP3153508||2034-06-09||See Plans and Pricing|
|Tamibarotene||Spain||ES2792851||2034-06-09||See Plans and Pricing|
|Tamibarotene||Japan||JP2019206529||2034-06-09||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|